Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 29337E102 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
FMR LLC
13G/A
|
15.0% |
8/6/2026
Event 6/30/2026
|
||
| FMR LLC | 15.0% | |||
| Abigail P. Johnson | 15.0% | |||
|
Orbimed Advisors LLC
13D/A
|
9.5% |
6/24/2026
Event 6/22/2026
|
||
| Orbimed Advisors LLC | 9.5% | |||
| Orbimed Capital GP VII LLC | 9.2% | |||
| Orbimed Genesis GP LLC | 0.3% | |||
| Orbimed Capital LLC | 0% | |||
|
Polar Capital Holdings Plc
13G/A
|
8.5% |
6/22/2026
Event 3/31/2026
|
||
| Polar Capital Holdings Plc | 8.5% | |||
| Polar Capital LLP | 8.5% | |||
| Polar Capital Funds PLC - Biotechnology Fund | 8.5% | |||
|
Commodore Capital LP
13G/A
|
7.7% |
5/15/2026
Event 3/31/2026
|
||
| Commodore Capital LP | 7.7% | |||
| Commodore Capital Master LP | 7.7% | |||
| Robert Egen Atkinson | 7.7% | |||
| Michael Kramarz | 7.7% | |||
|
Vestal Point Capital, LP
13G/A
|
5.4% |
5/15/2026
Event 3/31/2026
|
||
| Vestal Point Capital, LP | 5.4% | |||
| Ryan Wilder | 5.4% | |||
| BlackRock, Inc. 13G/A | 5.1% |
7/17/2025
Event 6/30/2025
|
||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (2) | ||||
|
Fairmount Funds Management LLC
13G/A
|
3.1% |
5/15/2026
Event 3/31/2026
|
||
| Fairmount Funds Management LLC | 3.1% | |||
| Fairmount Healthcare Fund II L.P. | 3.1% | |||
| Peter Harwin | 3.1% | |||
| Kiselak Tomas | 3.1% | |||
|
Venrock Healthcare Capital Partners III, L.P.
13G/A
|
2.8% |
5/15/2026
Event 3/31/2026
|
||
| Venrock Healthcare Capital Partners III, L.P. | 2.8% | |||
| VHCP Co-Investment Holdings III, LLC | 2.8% | |||
| Venrock Healthcare Capital Partners EG, L.P. | 2.8% | |||
| VHCP Management III, LLC | 2.8% | |||
| VHCP Management EG, LLC | 2.8% | |||
| Nimish Shah | 2.8% | |||
| Bong Y. Koh | 2.8% | |||
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 4 | 3.04 k | $139 k |
| 2026 Q2 | 222 | 83.2 M | $4.13 B |
| 2026 Q1 | 185 | 63.2 M | $2.46 B |
| 2025 Q4 | 132 | 62.4 M | $961 M |
| 2025 Q3 | 138 | 59.4 M | $1.22 B |
| 2025 Q2 | 129 | 59.5 M | $1.19 B |
| 2025 Q1 | 127 | 49.9 M | $984 M |
| 2024 Q4 | 118 | 49.6 M | $1.12 B |
| 2024 Q3 | 107 | 47.7 M | $1.22 B |
| 2024 Q2 | 103 | 49.0 M | $1.15 B |
| 2024 Q1 | 78 | 44.6 M | $783 M |
| 2023 Q4 | 66 | 39.1 M | $542 M |
| 2023 Q3 | 64 | 39.1 M | $534 M |
| 2023 Q2 | 65 | 39.1 M | $798 M |
| 2023 Q1 | 48 | 33.6 M | $735 M |